Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2010; 25(11): 1739-1746 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /economics /therapeutic use; Benzenesulfonates /economics /therapeutic use; Carcinoma, Hepatocellular /drug therapy /economics /mortality; Cost-Benefit Analysis; Humans; Liver Neoplasms /drug therapy /economics /mortality; Markov Chains; Models, Economic; Niacinamide /analogs & Phenylurea Compounds; Pyridines /economics /therapeutic use; Randomized Controlled Trials as Topic; Survival Analysis; derivatives AccessionNumber 22010002115 Date bibliographic record published 02/03/2011 |